Letter to the Editor Regarding “The Challenges of Switching Therapies in an Evolving Multiple Biosimilars Landscape: A Narrative Review of Current Evidence”

Barbara Finck(Coherus BioSciences (United States)), Paul Walden(Coherus BioSciences (United States)), Robert B. Geller
Advances in Therapy
April 29, 2021
Cited by 2


Related Papers